



Dr. Joshua Lederberg Stanford University

Dear Dr. Lederberg,

In your column appearing in today's Stanford Daily you make reference to thaliodomide as a mutagenic chemical. I recall seeing a reference to thaliodomide in an article on heart transplants, though unfortunately I can't recall the source. The comment was made in this article that thaliodomide did not cause the deformities attributed to it. Rather, it suppressed the natural rejection mechanisms which in its absence would have caused a spontaneous abortion of the deformed fetus. This rejection suppressant quality, according to this article, is currently being used to good advantage in heart transplant cases.

Being completely a layman in the matter, I have no idea whether this is the case in fact. The author of the article, which probably appeared in a popular magazine, may easily have been misinformed. At any rate, I'm sure that you'll be interested in checking into the matter for your own information and would appreciate hearing your resolution of the matter.

Sincerely.

Kenneth R. Ayer

Department of Anthropology

Stanford

To be precise, I did not say that thalidomide was <u>mutagenic</u>, for it is not known to cause changes in DNA (genes), but rather on development.

I am sure that thalidomide is <u>not</u> widely used as an immunosuppressant, but some similar drugs (mercaptopurine) are also <u>teratogenic</u>. The speculation \*x you mention cannot be contradicted, but is not very appealing.

Without a more explicit text, it is hard for me to comment in more detail.

ナル